Prospective observational study of the long term hazards of biologic therapy in rheumatoid arthritis.
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BSRBR-RA
- 17 Jun 2017 Preliminary results (n= 417) presented at the 18th Annual Congress of the European League Against Rheumatism
- 30 Aug 2013 Planned end date changed from 31 Dec 2014 to 30 Sep 2018 as reported by United Kingdom Clinical Research Network record .
- 08 Aug 2013 Accrual to date is 73% according to United Kingdom Clinical Research Network record.